Drug Trial Radar · NCT03206138
Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.
Last checked: Nov 19, 2026Latest source record: Jul 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
May 30, 2017
Primary completion
Oct 2018
Study completion Oct 2018
Sponsor
- Lead sponsor
- Seoul St. Mary's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Genexine, Inc.
- First posted
- Jul 2, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 19 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to investigate the safety and efficacy of GX-188E administered IM plus local administration of GX-I7 or Imiquimod at cervix in subjects with cervical intraepithelial neoplasia (CIN) 3.
Conditions
- Cervical Intraepithelial Neoplasia 3
Interventions
GX-188E, GX-I7Biological
Experimental: 1mg of GX-188E administered IM using EP device 3 times and 3mg of GX-I7 administered in cervix 4 times.
GX-188E, ImiquimodBiological
1mg of GX-188E administered IM using EP device 3 times and 12.5mg of Imiquimod application at cervix 8 times.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio of subjects who have histopathological regression of cervical lesions to CIN 1 or less in HPV 16 or 18-associated CIN3 subjects.Time frame: at week 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul St. Mary's hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.